杜皮鲁玛
医学
特应性皮炎
安慰剂
皮肤病科
Janus激酶1
Janus激酶抑制剂
单克隆抗体
贾纳斯激酶
单克隆
药理学
受体
免疫学
内科学
抗体
替代医学
病理
作者
Thomas Bieber,Eric L. Simpson,Jonathan I. Silverberg,Diamant Thaçi,C. Paul,Andrew E. Pink,Yoko Kataoka,Chia-Yu Chu,Marco DiBonaventura,Ricardo Rojo,Jeremias Antinew,Ileana A. Ionita,Rodney Sinclair,Seth Forman,Jacek Zdybski,Pinaki Biswas,Bimal Malhotra,Fan Zhang,Hernan Valdez
标识
DOI：10.1056/nejmoa2019380
摘要
The oral Janus kinase 1 (JAK1) inhibitor abrocitinib, which reduces interleukin-4 and interleukin-13 signaling, is being investigated for the treatment of atopic dermatitis. Data from trials comparing JAK1 inhibitors with monoclonal antibodies, such as dupilumab, that block interleukin-4 receptors are limited.
科研通智能强力驱动
Strongly Powered by AbleSci AI
Hao
酸化土壤改良
Maestro_S
一条淡水鱼
zzz4743
OCDer
个性的紫菜
坚强的广山
shinysparrow
丹霞
SOLOMON
飞翔的霸天哥
gjww
互助遵法尚德
西红柿炒番茄
bravo
smottom
热切菩萨
寻寻觅觅呢
阿大呆呆
皖公网安备34019202002308
